On May 6, 2021 Zionexa reported to join GE Healthcare to further develop molecular imaging agents in oncology, all aimed at enabling more precise diagnosis, improved treatment decision-making and ultimately better clinical outcomes for patients (Press release, Zionexa, MAY 6, 2021, View Source [SID1234579390]).​

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Our mission has always been to help physicians personalize treatment to improve patients’ pathway and quality of life. We are delighted to be joining an organization rooted in precision health.

Kevin O’Neill, President and CEO of GE Healthcare Pharmaceutical Diagnostics, said: "Like GE Healthcare, Zionexa’s products are aimed at enabling more precise diagnosis, improved treatment decision-making and ultimately better clinical outcomes for patients. This acquisition further demonstrates our commitment to enabling precision health and providing innovations that support oncologists, nuclear medicine specialists and other physicians throughout a cancer patient’s journey, from initial screening and diagnosis to informing therapy selection and monitoring the effectiveness of treatment."

Olivier Carli, President of Denos, the majority owner of Zionexa, said: "We expect GE Healthcare Pharmaceutical Diagnostics’ acquisition to allow Zionexa to accelerate the development of its promising R&D pipeline as well as its commercial footprint, while providing Zionexa’s team with access to global and complementary expertise

On May 6, 2021 CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, reported that it will host a conference call and live audio webcast on Thursday, May 13, 2021 at 4:30 p.m. Eastern Time to discuss financial results for the first quarter ended March 31, 2021 and to provide a business update (Press release, CymaBay Therapeutics, MAY 6, 2021, View Source [SID1234579389]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference Call Details
To access the live conference call, please dial 877-407-0784 from the U.S. and Canada, or 201-689-8560 internationally, Conference ID# 13718350. To access the live and subsequently archived webcast of the conference call, go to the Investors section of the company’s website at View Source

On May 6, 2021 Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, reported the Company will release its first quarter 2021 financial results before the market opens on Thursday, May 13, 2021 (Press release, Synlogic, MAY 6, 2021, View Source [SID1234579388]). The press release will be followed by a conference call at 8:30 am ET, which will be open to the public via telephone and webcast. During the conference call, the Company will review its financial results and provide a corporate update.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The conference call dial-in numbers are (844) 815-2882 for domestic callers and (213) 660-0926 for international callers. The conference ID number for the call is 2526209. Participants may access the live webcast via a link on the Synlogic website in the Events Calendar of the Investors and Media section. For those unable to participate in the conference call or webcast, a replay will be available for 30 days on the Company’s website.

On May 6, 2021 UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, reported that it will report first quarter 2021 financial results on Thursday, May 13, 2021, prior to the open of the market (Press release, UroGen Pharma, MAY 6, 2021, View Source [SID1234579387]). The announcement will be followed by a live audio webcast and conference call at 8:30 AM Eastern Time.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Audio Webcast
The webcast will be made available on the Investors section of the Company’s website at View Source Following the live audio webcast, a replay will be available on the Company’s website for approximately 30 days.

On May 6, 2021 Leidos (NYSE:LDOS), a FORTUNE 500 science and technology leader, reported that it was recently named as an awardee for the Defense Intelligence Agency’s (DIA) Solutions for the Information Technology Enterprise III (SITE III) contract vehicle (Press release, Leidos, MAY 6, 2021, View Source [SID1234579386]). The 10-year multiple-award contract holds a total estimated value of $12.6 billion. As an awardee, Leidos will continue supporting DIA and compete for task orders to support the overall program. SITE III is DIA’s third consecutive Indefinite Delivery/Indefinite Quantity (IDIQ) contract to address the evolving information technology (IT) requirements vital to the security of the United States. The contract facilitates worldwide coverage for integrated IT intelligence requirements and technical support services to the DIA and National Geospatial-Intelligence Agency (NGA).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"DIA’s decision to award Leidos the SITE III contract represents their trust in our IT prowess and our proven success securing sensitive assets and critical infrastructure, systems and applications," said Leidos Intelligence Group President Vicki Schmanske. "Our customers are constantly faced with unrelenting threats and adversaries, and this award allows us to help combat these threats. We’re proud to continue our support of DIA and the agency’s national security missions at home and around the world."

The SITE III IDIQ contract provides a centralized and synchronized IT acquisition capability to meet worldwide security requirements and technical support services. Leidos will support this effort through system design, development, fielding and sustainment of global intelligence and command and control assets.